Dr. Sacha Project End Date
30-June-2025:
* In specific aim 3, we will determine the length of time a single injection of the clinical dose can protect against vaginal transmission in cycling female macaques. These studies will determine the optimal clinical dosing of long-acting Leronlimab and lay the foundation for testing long-acting Leronlimab clinically as PREP in individuals at high-risk of acquiring HIV via sexual transmission."
https://reporter.nih.gov/search/MqjH24xtlU-kk...escription
1 year ago.
I have no doubt we are also planning to apply L-Leronlimab to our priority indication, mCRC
If we're designing LAL for Hiv, then surely also for our Registration trial, mCRC:
& jump to this from FDA:
Yes, an improved drug formulation can be submitted during an accelerated approval process, particularly through Fast Track or Breakthrough Therapy designations, which facilitate early, frequent communication and rolling reviews."
If, if, if an improved LL is later Amended into mCRC, it could very well be bye-bye to alot of ICI's
Ironically 3 yrs ago, in an SEC filing, it was said Leronlimab could replace need for ICI's
Have always said if that is true, Dr. J has always approached in a correct way:
Letting the data speak & be what you are following into.
Nice how everything is unfolding & including the potential paths
3
